MCID: ALK015
MIFTS: 42

Alk-Positive Anaplastic Large Cell Lymphoma

Categories: Cancer diseases, Immune diseases, Blood diseases, Rare diseases

Aliases & Classifications for Alk-Positive Anaplastic Large Cell Lymphoma

MalaCards integrated aliases for Alk-Positive Anaplastic Large Cell Lymphoma:

Name: Alk-Positive Anaplastic Large Cell Lymphoma 55
Anaplastic Large Cell Lymphoma, Alk-Positive 69
Anaplastic Large Cell Lymphoma, Alk Negative 69
Alk+ Anaplastic Large Cell Lymphoma 55
Alk+ Alcl 55

Characteristics:

Orphanet epidemiological data:

55
alk-positive anaplastic large cell lymphoma
Inheritance: Not applicable; Age of onset: Adolescent,Adult,Childhood;

Classifications:



External Ids:

Orphanet 55 ORPHA300895
ICD10 via Orphanet 33 C84.6
ICD10 32 C84.6 C84.7

Summaries for Alk-Positive Anaplastic Large Cell Lymphoma

MalaCards based summary : Alk-Positive Anaplastic Large Cell Lymphoma, also known as anaplastic large cell lymphoma, alk-positive, is related to leukemia, chronic lymphocytic and anaplastic large cell lymphoma. An important gene associated with Alk-Positive Anaplastic Large Cell Lymphoma is ALK (ALK Receptor Tyrosine Kinase), and among its related pathways/superpathways are ERK Signaling and Cytokine Signaling in Immune system. The drugs Dexamethasone and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include bone, nk cells and bone marrow, and related phenotypes are endocrine/exocrine gland and neoplasm

Related Diseases for Alk-Positive Anaplastic Large Cell Lymphoma

Diseases related to Alk-Positive Anaplastic Large Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 39)
# Related Disease Score Top Affiliating Genes
1 leukemia, chronic lymphocytic 29.5 CCND3 MCL1 STAT3
2 anaplastic large cell lymphoma 29.3 ALK JAK3 MCL1 MUC1 NPM1 STAT3
3 alk-negative anaplastic large cell lymphoma 11.5
4 lymphoma 11.1
5 lymphomatoid papulosis 10.2 ALK NPM1
6 hemophagocytic lymphohistiocytosis 10.2
7 leukemia 10.2
8 lymphatic system cancer 10.2 ALK NPM1
9 inflammatory myofibroblastic tumor 10.1 ALK NPM1
10 tetraploidy 10.1
11 neurofibromatosis, type iv, of riccardi 10.1
12 hypoxia 10.1
13 mycobacterium tuberculosis 1 10.1
14 leukemia, chronic myeloid 10.1
15 intravascular large b-cell lymphoma 10.1
16 b-cell lymphomas 10.1
17 esophagitis 10.1
18 adenocarcinoma 10.1
19 inflammatory breast carcinoma 10.1
20 hodgkin's lymphoma, lymphocytic-histiocytic predominance 10.1
21 gastroduodenitis 10.1
22 leukemia, chronic lymphocytic 2 10.1
23 myeloid leukemia 10.1
24 blood group, i system 10.1
25 leukemia, b-cell, chronic 10.1
26 intraneural perineurioma 9.9 ALK MUC1
27 malignant fibroxanthoma 9.9 ALK MUC1
28 eccrine porocarcinoma 9.9 MUC1 STAT3
29 mucinous adenocarcinoma 9.8 ALK MUC1
30 pneumothorax 9.8 ALK MUC1
31 diffuse large b-cell lymphoma 9.7 ALK STAT3
32 leukemia, acute myeloid 9.7 MCL1 NPM1 STAT3
33 myeloma, multiple 9.7 CCND3 MCL1 STAT3
34 mesothelioma, malignant 9.6 MCL1 MUC1
35 pancreatic ductal adenocarcinoma 9.6 MUC1 STAT3
36 primary cutaneous anaplastic large cell lymphoma 9.6 ALK MUC1 NPM1
37 cell type cancer 9.6 ALK MUC1
38 lymphoma, non-hodgkin, familial 9.5 ALK CCND3 MCL1 NPM1
39 reticulosarcoma 9.2 ALK CCND3 MUC1 NPM1

Graphical network of the top 20 diseases related to Alk-Positive Anaplastic Large Cell Lymphoma:



Diseases related to Alk-Positive Anaplastic Large Cell Lymphoma

Symptoms & Phenotypes for Alk-Positive Anaplastic Large Cell Lymphoma

MGI Mouse Phenotypes related to Alk-Positive Anaplastic Large Cell Lymphoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.35 ALK CCND3 JAK3 MCL1 STAT3
2 neoplasm MP:0002006 8.92 ALK CCND3 NPM1 STAT3

Drugs & Therapeutics for Alk-Positive Anaplastic Large Cell Lymphoma

Drugs for Alk-Positive Anaplastic Large Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 63)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
2
Doxorubicin Approved, Investigational Phase 2,Phase 1 23214-92-8 31703
3
Daunorubicin Approved Phase 2 20830-81-3 30323
4
Vincristine Approved, Investigational Phase 1, Phase 2 2068-78-2, 57-22-7 5978
5
Etoposide Approved Phase 2,Phase 1 33419-42-0 36462
6
Cytarabine Approved, Investigational Phase 2 147-94-4 6253
7
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
8
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
9
Ifosfamide Approved Phase 2 3778-73-2 3690
10
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
11
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
12
Cortisone acetate Approved, Investigational Phase 1, Phase 2 1950-04-4, 50-04-4 5745
13
Crizotinib Approved Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
14
Prednisone Approved, Vet_approved Phase 1, Phase 2 53-03-2 5865
15
Ceritinib Approved Phase 1, Phase 2 1032900-25-6
16
alemtuzumab Approved, Investigational Phase 2 216503-57-0
17
leucovorin Approved, Nutraceutical Phase 2 58-05-9 143 6006
18
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
19
Doxil Approved June 1999 Phase 2,Phase 1 31703
20 Podophyllotoxin Phase 2,Phase 1 518-28-5
21
Cortisone Phase 1, Phase 2 53-06-5 222786
22 Dexamethasone acetate Phase 2 1177-87-3
23 Isophosphamide mustard Phase 2 0
24 Alkylating Agents Phase 2,Phase 1
25 glucocorticoids Phase 2,Phase 1
26
protease inhibitors Phase 2
27 Folic Acid Antagonists Phase 2
28 Gastrointestinal Agents Phase 2
29 Topoisomerase Inhibitors Phase 2,Phase 1
30 HIV Protease Inhibitors Phase 2
31 Nucleic Acid Synthesis Inhibitors Phase 2
32 Hormone Antagonists Phase 2,Phase 1
33 Dermatologic Agents Phase 2,Phase 1
34 Vitamin B Complex Phase 2
35 Angiogenesis Inhibitors Phase 1, Phase 2
36 Hormones Phase 2,Phase 1
37 Angiogenesis Modulating Agents Phase 1, Phase 2
38 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2,Phase 1
39 Peripheral Nervous System Agents Phase 2
40 Antibodies, Monoclonal Phase 1, Phase 2
41 Anti-Bacterial Agents Phase 2,Phase 1
42 Antiemetics Phase 2
43 Anti-Infective Agents Phase 2,Phase 1
44 Immunoglobulins Phase 1, Phase 2
45 Etoposide phosphate Phase 2,Phase 1
46 Immunosuppressive Agents Phase 2,Phase 1
47 Antimetabolites Phase 2
48 Anti-Inflammatory Agents Phase 2,Phase 1
49 Antimetabolites, Antineoplastic Phase 2
50 Keratolytic Agents Phase 2,Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma Recruiting NCT02729961 Phase 1, Phase 2 Brentuximab Vedotin;Ceritinib
2 Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas Recruiting NCT02419287 Phase 2 crizotinib
3 Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma Recruiting NCT01979536 Phase 2 Brentuximab Vedotin;Crizotinib;Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Methotrexate
4 Combination Chemotherapy and Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma Recruiting NCT02561273 Phase 1, Phase 2 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Lenalidomide;Prednisone;Vincristine Sulfate
5 Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma Recruiting NCT03113500 Phase 2 Brentuximab Vedotin;Cyclophosphamide;Doxorubicin;Etoposide;Prednisone
6 Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas Active, not recruiting NCT00069238 Phase 2 EPOCH

Search NIH Clinical Center for Alk-Positive Anaplastic Large Cell Lymphoma

Genetic Tests for Alk-Positive Anaplastic Large Cell Lymphoma

Anatomical Context for Alk-Positive Anaplastic Large Cell Lymphoma

MalaCards organs/tissues related to Alk-Positive Anaplastic Large Cell Lymphoma:

38
Bone, Nk Cells, Bone Marrow, Breast, Testes, Myeloid, B Cells

Publications for Alk-Positive Anaplastic Large Cell Lymphoma

Articles related to Alk-Positive Anaplastic Large Cell Lymphoma:

(show top 50) (show all 105)
# Title Authors Year
1
Prognostic impact of minimal disseminated disease and immune response to NPM-ALK in Japanese children with ALK-positive anaplastic large cell lymphoma. ( 29030834 )
2018
2
Phase II trial of CH5424802 (alectinib hydrochloride) for recurrent or refractory ALK-positive anaplastic large cell lymphoma: study protocol for a non-randomized non-controlled trial. ( 28878445 )
2017
3
Minimal Change Disease as Initial Presentation of ALK-Positive Anaplastic Large-Cell Lymphoma in a Pediatric Patient. ( 29279700 )
2017
4
Partial deletion of the ALK gene in ALK-positive anaplastic large cell lymphoma. ( 28665006 )
2017
5
ALK-positive anaplastic large cell lymphoma with soft tissue involvement in a young woman [Retraction]. ( 29296088 )
2017
6
Crizotinib in Combination with Everolimus Synergistically Inhibits Proliferation of ALK-Positive Anaplastic Large Cell Lymphoma. ( 28675026 )
2017
7
ALK-positive anaplastic large cell lymphoma undiagnosed in a patient with tuberculosis: a case report and review of the literature. ( 28490385 )
2017
8
Arsenic trioxide degrades NPM-ALK fusion protein and inhibits growth of ALK-positive anaplastic large cell lymphoma. ( 27795556 )
2016
9
ALK-positive anaplastic large-cell lymphoma with marked leukemoid reaction and hemophagocytic lymphohistiocytosis. ( 27563714 )
2016
10
Remission of an extensively pre-treated relapsing/refractory ALK-positive anaplastic large cell lymphoma following metronomic therapy. ( 26734914 )
2016
11
Fine-needle aspiration cytology yield as a basis for morphological, molecular, and cytogenetic diagnosis in alk-positive anaplastic large cell lymphoma with atypical clinical presentation. ( 27468968 )
2016
12
Successful allogeneic bone marrow transplantation with reduced intensity conditioning regimen for a pediatric relapsed ALK positive anaplastic large cell lymphoma. ( 27498729 )
2016
13
Primary central nervous system ALK-positive anaplastic large cell lymphoma in an adult: A rare case report. ( 27930548 )
2016
14
A positive feedback loop involving the Wnt/I^-catenin/MYC/Sox2 axis defines a highly tumorigenic cell subpopulation in ALK-positive anaplastic large cell lymphoma. ( 27821172 )
2016
15
ALK-positive anaplastic large cell lymphoma with soft tissue involvement in a young woman. ( 27445489 )
2016
16
ALK positive Anaplastic Large Cell Lymphoma of the Thoracic Spine. ( 27761194 )
2016
17
ALK-positive anaplastic large cell lymphoma with prominent bone involvement in a 13-year-old boy. ( 26834485 )
2016
18
Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes. ( 27793034 )
2016
19
Intra-abdominal ALK-positive anaplastic large cell lymphoma in a patient with neurofibromatosis type 1. ( 26272700 )
2015
20
Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma. ( 25421750 )
2015
21
Endobronchial ALK-Positive Anaplastic Large Cell Lymphoma Presenting Massive Hemoptysis. ( 26508931 )
2015
22
ALK-positive anaplastic large cell lymphoma: an evolving story. ( 25961700 )
2015
23
The NADPH oxidase NOX5 protects against apoptosis in ALK-positive anaplastic large-cell lymphoma cell lines. ( 25797883 )
2015
24
Metachronous classical Hodgkin's lymphoma and ALK-positive anaplastic large cell lymphoma. ( 25938345 )
2015
25
MicroRNA and ALK-positive anaplastic large cell lymphoma. ( 25961697 )
2015
26
ALK-positive anaplastic large cell lymphoma presenting with hemophagocytic lymphohistiocytosis. ( 26114236 )
2015
27
Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma. ( 26338968 )
2015
28
ALK-positive anaplastic large cell lymphoma with prominent bone involvement. ( 26018037 )
2015
29
Silibinin suppresses NPM-ALK, potently induces apoptosis and enhances chemosensitivity in ALK-positive anaplastic large cell lymphoma. ( 26133723 )
2015
30
ALK Positive Anaplastic Large Cell Lymphoma Presenting as Extensive Bone Involvement. ( 25738071 )
2015
31
STAT1 is phosphorylated and downregulated by the oncogenic tyrosine kinase NPM-ALK in ALK-positive anaplastic large-cell lymphoma. ( 25921060 )
2015
32
Correction: Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma. ( 26420623 )
2015
33
Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma. ( 24509625 )
2014
34
Diagnosis of ALK-positive anaplastic large cell lymphoma based on CD30 testing. ( 25855891 )
2014
35
Diagnosis of ALK-positive anaplastic large cell lymphoma based on CD30 testing. ( 24852617 )
2014
36
Brain metastasis of ALK positive anaplastic large cell lymphoma after a long-term disease free survival in an old adult. ( 24696735 )
2014
37
ALK-positive anaplastic large cell lymphoma with an unusual alveolar growth pattern. ( 25674293 )
2014
38
Editor in Chief: Response to Eyre etA al. "ALK-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease" ( 24953081 )
2014
39
Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK-positive anaplastic large-cell lymphoma. ( 24297868 )
2014
40
STAT3-mediated activation of microRNA cluster 17~92 promotes proliferation and survival of ALK-positive anaplastic large cell lymphoma. ( 23975180 )
2014
41
ALK Positive Anaplastic Large Cell Lymphoma With Pure Leptomeningeal Involvement: Unique Case Report and Review of the Literature. ( 24407988 )
2014
42
Anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma (ALCL) of breast in a patient without a breast implant. ( 25971833 )
2014
43
Primary central nervous system ALK positive anaplastic large cell lymphoma with predominantly leptomeningeal involvement in an adult. ( 23549832 )
2013
44
Identification of a novel crosstalk between casein kinase 2I+ and NPM-ALK in ALK-positive anaplastic large cell lymphoma. ( 23153582 )
2013
45
Use of targeted therapy for refractory ALK-positive anaplastic large cell lymphoma as a bridging strategy prior to allogeneic transplantation. ( 22820970 )
2013
46
Simultaneous cytomorphological and multiparameter flow cytometric analysis of ALK-positive anaplastic large cell lymphoma in children. ( 23420373 )
2013
47
Leukemic phase of ALK-positive anaplastic large cell lymphoma. ( 23610781 )
2013
48
Disheveled proteins promote cell growth and tumorigenicity in ALK-positive anaplastic large cell lymphoma. ( 23022960 )
2013
49
ALK-positive anaplastic large cell lymphoma limited to the skin: clinical, histopathological and molecular analysis of 6 pediatric cases. A report from the ALCL99 study. ( 22773605 )
2013
50
ALK-positive anaplastic large cell lymphoma presenting as intradural spinal mass: first reported case and review of literature. ( 23082771 )
2013

Variations for Alk-Positive Anaplastic Large Cell Lymphoma

Expression for Alk-Positive Anaplastic Large Cell Lymphoma

Search GEO for disease gene expression data for Alk-Positive Anaplastic Large Cell Lymphoma.

Pathways for Alk-Positive Anaplastic Large Cell Lymphoma

Pathways related to Alk-Positive Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.4 ALK CCND3 JAK3 MUC1 STAT3
2
Show member pathways
12.97 JAK3 MCL1 MUC1 STAT3
3
Show member pathways
12.19 JAK3 MCL1 STAT3
4 12.18 ALK CCND3 JAK3 STAT3
5
Show member pathways
11.88 CCND3 JAK3 STAT3
6 11.74 CCND3 JAK3 STAT3
7
Show member pathways
11.64 CCND3 JAK3 MCL1 STAT3
8
Show member pathways
11.5 MCL1 STAT3
9 11.41 CCND3 MCL1
10 11.36 CCND3 STAT3
11
Show member pathways
11.34 CCND3 JAK3
12 11.31 MCL1 NPM1
13
Show member pathways
11.1 JAK3 STAT3
14
Show member pathways
11.06 JAK3 STAT3
15 11.01 JAK3 STAT3
16 10.98 JAK3 MCL1 MUC1 STAT3
17 10.91 CCND3 STAT3

GO Terms for Alk-Positive Anaplastic Large Cell Lymphoma

Biological processes related to Alk-Positive Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of apoptotic process GO:0042981 9.43 ALK JAK3 MCL1
2 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.37 MUC1 NPM1
3 response to cytokine GO:0034097 9.32 MCL1 STAT3
4 interleukin-7-mediated signaling pathway GO:0038111 9.16 JAK3 STAT3
5 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 8.96 JAK3 STAT3
6 interleukin-15-mediated signaling pathway GO:0035723 8.62 JAK3 STAT3

Molecular functions related to Alk-Positive Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.13 CCND3 NPM1 STAT3
2 protein phosphatase binding GO:0019903 8.62 JAK3 STAT3

Sources for Alk-Positive Anaplastic Large Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....